Home Featured 2

Featured 2

Featured posts

Most popular

The Changing the Landscape of Tobacco Products: Potential Effects of ENDS and HTPs

lungcanc

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

Potential Improvement in Lung Cancer Deaths and Overall Mortality With Integration of Smoking Cessation and Lung Cancer Screening

Q&A with Lead ALCHEMIST Investigator, Dr. Ramaswamy Govindan

Milestones in Lung Cancer Treatment

KEYNOTE-010: Long-Term Outcomes and Results of Retreatment

lungcanc

Sublobar Resections for Early Lung Cancer

lungcanc

Diagnostic Oncology: Reports from the IASLC Pathology Committee

lungcanc

Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint...

lungcanc

Sustained Funding Vital for Smoking-Cessation Efforts

lungcanc

Paul Bunn

The Peaks and Valleys in Lung Cancer Therapeutics Research

lungcanc

Disparities in Meeting Eligibility Criteria for Lung Cancer Screening

lungcanc

Can E-Cigarettes Help Patients Stop Smoking Combustible Cigarettes?

lungcanc

TTFields in Unresectable MPM: STELLAR Results in Practice

lungcanc

Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for...

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib